Ignite Creation Date:
2025-12-25 @ 1:38 AM
Ignite Modification Date:
2026-01-22 @ 1:19 PM
Study NCT ID:
NCT06504394
Status:
RECRUITING
Last Update Posted:
2025-12-01
First Post:
2024-07-11
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-10-14
Start Date Type:
ACTUAL
Primary Completion Date:
2028-11-08
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-11-08
Completion Date Type:
ESTIMATED
First Submit Date:
2024-07-11
First Submit QC Date:
None
Study First Post Date:
2024-07-16
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-27
Last Update Post Date:
2025-12-01
Last Update Post Date Type:
ESTIMATED